Trial Profile
Effect of BRAF or combined BRAF and MEK inhibitors on efficacy and long-term survival in metastatic melanoma patients
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 05 Dec 2015
Price :
$35
*
At a glance
- Drugs Dabrafenib (Primary) ; Trametinib (Primary)
- Indications Malignant melanoma
- Focus Therapeutic Use
- 05 Dec 2015 New trial record